BFC Planning, Inc.’s Myriad Genetics MYGN Stock Holding History

BFC Planning, Inc.’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-195	Closed	-$1.11K	–	3562
2026 Q2	$1.11K	Buy	+195	New	+$885	﹤0.01%	3125

Other funds holding MYGN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

BFC Planning, Inc.'s MYGN Position: Q3 2026 in Review

BFC Planning, Inc. sold out of Myriad Genetics (MYGN) in Q3 2026, closing a stake of 195 shares — an estimated $1.11K sold.

BFC Planning, Inc. first reported a position in MYGN in Q2 2026 and held it in 1 quarter. The position peaked at $1.11K in Q2 2026. 126 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

BFC Planning, Inc. reported no remaining Myriad Genetics position as of Q3 2026 after selling out during the quarter.
BFC Planning, Inc. sold 195 Myriad Genetics shares in Q3 2026, an estimated $1.11K.
BFC Planning, Inc. first reported a position in Myriad Genetics in Q2 2026 and held it in 1 quarter.
BFC Planning, Inc.'s Myriad Genetics position peaked at $1.11K in Q2 2026.
126 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on BFC Planning, Inc.'s 13F filing for Q3 2026, filed 13 Nov 2026.